1832 related articles for article (PubMed ID: 17616482)
1. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
Dubois B; Feldman HH; Jacova C; Dekosky ST; Barberger-Gateau P; Cummings J; Delacourte A; Galasko D; Gauthier S; Jicha G; Meguro K; O'brien J; Pasquier F; Robert P; Rossor M; Salloway S; Stern Y; Visser PJ; Scheltens P
Lancet Neurol; 2007 Aug; 6(8):734-46. PubMed ID: 17616482
[TBL] [Abstract][Full Text] [Related]
2. Personalized medicine in Alzheimer's disease and depression.
Souslova T; Marple TC; Spiekerman AM; Mohammad AA
Contemp Clin Trials; 2013 Nov; 36(2):616-23. PubMed ID: 23816492
[TBL] [Abstract][Full Text] [Related]
3. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
Wallin AK; Blennow K; Andreasen N; Minthon L
Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
[TBL] [Abstract][Full Text] [Related]
5. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach.
Hogervorst E; Bandelow S; Combrinck M; Irani SR; Smith AD
Dement Geriatr Cogn Disord; 2003; 16(3):170-80. PubMed ID: 12826744
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study.
Gabelle A; Dumurgier J; Vercruysse O; Paquet C; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Buée L; Pasquier F; Hugon J; Touchon J; Lehmann S
J Alzheimers Dis; 2013; 34(1):297-305. PubMed ID: 23186986
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
8. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
Shoji M
Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
[TBL] [Abstract][Full Text] [Related]
9. [A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].
Molinuevo JL; Gispert JD; Pujol J; Rojas S; Lladó A; Balasa M; Antonell A; Sánchez-Valle R; Rami L
Rev Neurol; 2012 May; 54(9):513-22. PubMed ID: 22532214
[TBL] [Abstract][Full Text] [Related]
10. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in atypical degenerative dementias of the Alzheimer type.
Wagner M; Teichner G; Bachman DL
Arch Clin Neuropsychol; 2003 Dec; 18(8):893-903. PubMed ID: 14609583
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Alzheimer's disease: the present and the future.
Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A
Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
Ivanoiu A; Sindic CJ
Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
[TBL] [Abstract][Full Text] [Related]
15. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
[TBL] [Abstract][Full Text] [Related]
16. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.
Bouwman FH; Verwey NA; Klein M; Kok A; Blankenstein MA; Sluimer JD; Barkhof F; van der Flier WM; Scheltens P
Dement Geriatr Cogn Disord; 2010; 30(1):1-7. PubMed ID: 20606438
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria.
Carrillo MC; Dean RA; Nicolas F; Miller DS; Berman R; Khachaturian Z; Bain LJ; Schindler R; Knopman D;
Alzheimers Dement; 2013 Sep; 9(5):594-601. PubMed ID: 24007744
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease.
Rosén C; Zetterberg H
Curr Opin Psychiatry; 2013 May; 26(3):276-82. PubMed ID: 23493130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
